342 results on '"Donadio M"'
Search Results
2. Ab-initio simulation of photoinduced transformation of small rings in amorphous silica
- Author
-
Bernasconi, D. Donadio M.
- Subjects
Condensed Matter - Materials Science - Abstract
We have studied the photoinduced transformation of small rings (3-membered) in amorphous silica by Car-Parrinello simulations. The process of ring opening leading to the formation of a couple of paramagnetic centers, namely an E' and a non-bridging-oxygen hole center (NBOHC), has been proposed experimentally to occur in silica exposed to F2 laser irradiation (at 7.9 eV). By using a new scheme for the simulation of rare events in ab-initio molecular dynamics (Iannuzzi, Laio and Parrinello, Phys. Rev. Lett. 90, 238303 (2003)), we have identified the transformation path for the opening of a 3-membered ring induced by a self-trapped triplet exciton, the migration of NBOHC and formation of a couple of stable E' and NBOHC paramagnetic defects.
- Published
- 2004
3. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies
- Author
-
Cazzaniga, M, Verusio, C, Ciccarese, M, Fumagalli, A, Sartori, D, Valerio, M, Airoldi, M, Moretti, G, Ficorella, C, Gianni, L, Michelotti, A, Zambelli, A, Febbraro, A, Generali, D, Pistelli, M, Garrone, O, Musolino, A, Vici, P, Maur, M, Mentuccia, L, La Verde, N, Bianchi, G, Artale, S, Blasi, L, De Laurentiis, M, Atzori, F, Turletti, A, Porpiglia, M, Santini, D, Fabi, A, Gebbia, V, Schirone, A, Palumbo, R, Ferzi, A, Frassoldati, A, Scavelli, C, Clivio, L, Giordano, M, Donadio, M, Biganzoli, L, Del Mastro, L, Bisagni, G, Livi, L, Natoli, C, Montemurro, F, Riccardi, F, Romagnoli, E, Marchetti, P, Torri, V, Pronzato, P, Mustacchi, G, Cazzaniga M. E., Verusio C., Ciccarese M., Fumagalli A., Sartori D., Valerio M. R., Airoldi M., Moretti G., Ficorella C., Gianni L., Michelotti A., Zambelli A., Febbraro A., Generali D., Pistelli M., Garrone O., Musolino A., Vici P., Maur M., Mentuccia L., La Verde N., Bianchi G. V., Artale S., Blasi L., De Laurentiis M., Atzori F., Turletti A., Porpiglia M., Santini D., Fabi A., Gebbia V., Schirone A., Palumbo R., Ferzi A., Frassoldati A., Scavelli C., Clivio L., Giordano M., Donadio M., Biganzoli L., Del Mastro L., Bisagni G., Livi L., Natoli C., Montemurro F., Riccardi F., Romagnoli E., Marchetti P., Torri V., Pronzato P., Mustacchi G., Cazzaniga, M, Verusio, C, Ciccarese, M, Fumagalli, A, Sartori, D, Valerio, M, Airoldi, M, Moretti, G, Ficorella, C, Gianni, L, Michelotti, A, Zambelli, A, Febbraro, A, Generali, D, Pistelli, M, Garrone, O, Musolino, A, Vici, P, Maur, M, Mentuccia, L, La Verde, N, Bianchi, G, Artale, S, Blasi, L, De Laurentiis, M, Atzori, F, Turletti, A, Porpiglia, M, Santini, D, Fabi, A, Gebbia, V, Schirone, A, Palumbo, R, Ferzi, A, Frassoldati, A, Scavelli, C, Clivio, L, Giordano, M, Donadio, M, Biganzoli, L, Del Mastro, L, Bisagni, G, Livi, L, Natoli, C, Montemurro, F, Riccardi, F, Romagnoli, E, Marchetti, P, Torri, V, Pronzato, P, Mustacchi, G, Cazzaniga M. E., Verusio C., Ciccarese M., Fumagalli A., Sartori D., Valerio M. R., Airoldi M., Moretti G., Ficorella C., Gianni L., Michelotti A., Zambelli A., Febbraro A., Generali D., Pistelli M., Garrone O., Musolino A., Vici P., Maur M., Mentuccia L., La Verde N., Bianchi G. V., Artale S., Blasi L., De Laurentiis M., Atzori F., Turletti A., Porpiglia M., Santini D., Fabi A., Gebbia V., Schirone A., Palumbo R., Ferzi A., Frassoldati A., Scavelli C., Clivio L., Giordano M., Donadio M., Biganzoli L., Del Mastro L., Bisagni G., Livi L., Natoli C., Montemurro F., Riccardi F., Romagnoli E., Marchetti P., Torri V., Pronzato P., and Mustacchi G.
- Abstract
Background: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. Methods: For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). Results: Eighty-one and 91 patients have been identified from the two data sets. The median age was 63 years (range 35-82) for the EVA and 57.8 years (range 35.0-82.3) for the AMBRA patients. ORRs were 23.5 and 24.3% in the whole population, 26.9% in the patients with bone only, and 21.8 and 21.4% in those with visceral metastases. The median duration of HD-FUL was 11.6 months (range 1-48) and 12.4 months (range 2.9-70.0) in the two data sets, respectively. Conclusion: These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients.
- Published
- 2020
4. C14 - From the CLEOPATRA study to real life: preliminary results from the G.O.N.O. SUPER trial
- Author
-
Garrone, O., Cursano, M.C., De Angelis, C., Giarratano, T., Saggia, C., Beano, A., Cazzaniga, M., La Verde, N., Milani, A., Collovà, E., Coltelli, L., de Conciliis, E., Vandone, A.M., Airoldi, M., D'Onofrio, L., Bertolini, I., Guarneri, V., Donadio, M., Riva, F., and Merlano, M.C.
- Published
- 2017
- Full Text
- View/download PDF
5. C36 - Nab-paclitaxel in clinical practice: data from the MANTEL study
- Author
-
Vanella, P., Garrone, O., Saggia, C., Bergnolo, P., Beano, A., Airoldi, M., Turletti, A., Castiglione, F., Manzin, E., Denaro, N., de Conciliis, E., Vandone, A.M., Donadio, M., Miraglio, E., and Merlano, M.C.
- Published
- 2017
- Full Text
- View/download PDF
6. C33 - Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): focus on luminal cancers. Results from GIM13 - AMBRA study
- Author
-
Mustacchi, G., Cazzaniga, M., Giordano, M., Garrone, O., Donadio, M., Del Mastro, L., Livi, L., Natoli, C., Michelotti, A., Turletti, A., Riccardi, F., Marchetti, P., Montemurro, F., Romagnoli, E., De Placido, S., Biganzoli, L., Bisagni, G., and Bria, E.
- Published
- 2017
- Full Text
- View/download PDF
7. C25 - Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study
- Author
-
Pronzato, P., Mustacchi, G., Riccardi, F., Turletti, A., Michelotti, A., Natoli, C., Livi, L., Del Mastro, L., Donadio, M., Garrone, O., Giordano, M., De Laurentiis, M., Marchetti, P., Montemurro, F., Romagnoli, E., De Placido, S., Biganzoli, L., and Cazzaniga, M.
- Published
- 2017
- Full Text
- View/download PDF
8. Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?
- Author
-
Cazzaniga ME, Biganzoli L, Cortesi L, De Placido S, Donadio M, Fabi A, Ferro A, Generali D, Lorusso V, Milani A, Montagna E, Munzone E, Orlando L, Pizzuti L, Simoncini E, Zamagni C, and Pappagallo GL
- Subjects
advanced breast cancer ,vinorelbine ,quality of life ,metronomic chemotherapy ,tolerability ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,lcsh:RC254-282 - Abstract
Marina Elena Cazzaniga,1 Laura Biganzoli,2 Laura Cortesi,3 Sabino De Placido,4 Michela Donadio,5 Alessandra Fabi,6 Antonella Ferro,7 Daniele Generali,8,9 Vito Lorusso,10 Andrea Milani,11 Emilia Montagna,12 Elisabetta Munzone,12 Laura Orlando,13 Laura Pizzuti,6 Edda Simoncini,14 Claudio Zamagni,15 Giovanni L Pappagallo16 On behalf of the “Metronomic Chemotherapy in Advanced Breast Cancer” Study Group 1Medical Oncology Unit & Phase 1 Research Unit, ASST Monza, Monza, Italy; 2Medical Oncology Division, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy; 3Haematology and Oncology Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy; 4Clinical Medicine and Surgery Department, University of Naples Federico II, Naples, Italy; 5Medical Oncology Breast Unit, AOU Città della Salute e della Scienza, Turin, Italy; 6Oncology Unit 1, Regina Elena National Cancer Institute, Rome, Italy; 7Medical Oncology Unit, Santa Chiara Hospital, Trento, Italy; 8Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy; 9UO Multidisciplinare di Patologia Mammaria e Ricerca Traslazionale, ASST di Cremona, Cremona, Italy; 10Operative Unit of Medical Oncology, Oncology Institute of Bari, Bari, Italy; 11Division of Investigative Clinical Oncology, Candiolo Cancer Institute – FPO, IRCCS, Candiolo, Italy; 12Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy; 13Medical Oncology & Breast Unit, “Antonio Perrino” Hospital, Brindisi, Italy; 14Breast Unit, ASST Spedali Civili di Brescia, Brescia, Italy; 15SSD Medical Oncology Addarii, Policlinico Sant’Orsola Malpighi, Bologna, Italy; 16Medical Oncology Unit, Azienda ULSS 3 Serenissima, Mirano-Dolo, ItalyAbstract: The prognosis for patients with locally advanced or metastatic breast cancer (mBC) remains poor, with a median survival of 2–4years. About 10% of newly diagnosed breast cancer patients present with metastatic disease, and 30%–50% of those diagnosed at earlier stages will subsequently progress to mBC. In terms of ongoing management for advanced/metastatic breast cancer after failure of hormonal therapy, there is a high medical need for new treatment options that prolong the interval to the start of intensive cytotoxic therapy, which is often associated with potentially serious side effects and reduced quality of life. Oral chemotherapeutic agents such as capecitabine and vinorelbine have demonstrated efficacy in patients with mBC, with prolonged disease control and good tolerability. Use of oral chemotherapy reduces the time and cost associated with treatment and is often more acceptable to patients than intravenous drug delivery. Metronomic administration of oral chemotherapy is therefore a promising treatment strategy for some patients with mBC and inhibits tumor progression via multiple mechanisms of action. Ongoing clinical trials are investigating metronomic chemotherapy regimens as a strategy to prolong disease control with favorable tolerability. This article provides an overview of metronomic chemotherapy treatment options in mBC, with perspectives on this therapy from a panel of experts. Keywords: advanced breast cancer, metronomic chemotherapy, vinorelbine, tolerability, quality of life
- Published
- 2019
9. P-201 Retrospective evaluation of patients with colorectal cancer with metastasis in the central nervous system: Clinical and epidemiological prognostic factors
- Author
-
Sá, D., primary, Donadio, M., additional, Cesca, M., additional, Loose, S., additional, and Mello, C., additional
- Published
- 2021
- Full Text
- View/download PDF
10. Biology, prognosis and response to therapy of breast carcinomas according to HER2 score
- Author
-
Ménard, S., Balsari, A., Tagliabue, E., Camerini, T., Casalini, P., Bufalino, R., Castiglioni, F., Carcangiu, M.L., Gloghini, A., Scalone, S., Querzoli, P., Lunardi, M., Molino, A., Mandarà, M., Mottolese, M., Marandino, F., Venturini, M., Bighin, C., Cancello, G., Montagna, E., Perrone, F., De Matteis, A., Sapino, A., Donadio, M., Battelli, N., Santinelli, A., Pavesi, L., Lanza, A., Zito, F.A., Labriola, A., Aiello, R.A., Caruso, M., Zanconati, F., Mustacchi, G., Barbareschi, M., Frisinghelli, M., Russo, R., and Carrillo, G.
- Published
- 2008
- Full Text
- View/download PDF
11. 41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial
- Author
-
Conte, P.F., primary, Frassoldati, A., additional, Bisagni, G., additional, Brandes, A.A., additional, Donadio, M., additional, Garrone, O., additional, Piacentini, F., additional, Cavanna, L., additional, Giotta, F., additional, Aieta, M., additional, Gebbia, V., additional, Musolino, A., additional, Ferro, A., additional, Danese, S., additional, Zamagni, C., additional, Nanni, O., additional, Dieci, M.V., additional, Vicini, R., additional, Balduzzi, S., additional, and Guarneri, V., additional
- Published
- 2021
- Full Text
- View/download PDF
12. A simple and reproducible prognostic index in luminal ER-positive breast cancers
- Author
-
Castellano, I., Chiusa, L., Vandone, A. M., Beatrice, S., Goia, M., Donadio, M., Arisio, R., Muscarà, F., Durando, A., Viale, G., Cassoni, P., and Sapino, A.
- Published
- 2013
- Full Text
- View/download PDF
13. Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial
- Author
-
Donadio, M., Manzin, E., Berruti, A., Bottini, A., Gorzegno, G., Danese, S., DeFabiani, E., Sarobba, M.G., Lorusso, V., Castiglione, F., Moro, G., Bertetto, O., Bumma, C., and Dogliotti, L.
- Published
- 2001
- Full Text
- View/download PDF
14. MAXIMAL EXERCISE TEST IN PATIENTS WITH CYSTIC FIBROSIS: 408
- Author
-
Hommerding, P. X., Baptista, R. R., Donadio, M. F., and Marostica, P. C.
- Published
- 2012
15. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience
- Author
-
Vandone, A. M., Donadio, M., Mozzati, M., Ardine, M., Polimeni, M. A., Beatrice, S., Ciuffreda, L., and Scoletta, M.
- Published
- 2012
- Full Text
- View/download PDF
16. POSTURAL AND BAROPODOMETRIC EVALUATION IN CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS: 398
- Author
-
Schindel, C. S., Hommerding, P. X., Baptista, R. R., Melo, D. A., Marostica, P. J., and Donadio, M. V.
- Published
- 2011
17. Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws
- Author
-
Arduino, P. G., Menegatti, E., Scoletta, M., Battaglio, C., Mozzati, M., Chiecchio, A., Berardi, D., Vandone, A. M., Donadio, M., Gandolfo, S., Scully, C., and Broccoletti, R.
- Published
- 2011
- Full Text
- View/download PDF
18. P-54 BISQUIT: A randomized phase II study of the administration of prebiotics and probiotics during definitive treatment with chemotherapy-radiotherapy for patients with squamous cell carcinoma of the anal canal
- Author
-
Riechelmann, R., primary, Camandaroba, M., additional, Mello, C., additional, Souza e Silva, V., additional, Felismino, T., additional, Jesus, V., additional, Barros e Silva, M., additional, Donadio, M., additional, Cavicchioli, M., additional, Aguiar, S., additional, Cobo, M., additional, Nunes, D., additional, and Dias-Neto, E., additional
- Published
- 2020
- Full Text
- View/download PDF
19. O-14 Young adults with neuroendocrine tumors present a high rate of pathogenic or likely pathogenic germline variants in cancer-predisposing genes
- Author
-
Riechelmann, R., primary, Paula, C. de, additional, Donadio, M., additional, Santiago, K., additional, Carvalho, N. de, additional, Carraro, D., additional, and Torrezan, G., additional
- Published
- 2020
- Full Text
- View/download PDF
20. P-55 GASTHER2: Efficacy of adding trastuzumab to standard chemotherapy in patients with advanced HER2-negative gastric cancer and HER2-positive expression in circulating tumor cells
- Author
-
Riechelmann, R., primary, Donadio, M., additional, Jesus, V., additional, Felismino, T., additional, Mello, C., additional, Silva, V. Souza e, additional, Silva, M. Barros e, additional, Camandaroba, M., additional, Rodrigues, N., additional, Dettino, A., additional, and Chinen, L., additional
- Published
- 2020
- Full Text
- View/download PDF
21. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
- Author
-
Gligorov, J, Ataseven, B, Verrill, M, de Laurentiis, M, Jung, K, Azim, H, Al-Sakaff, N, Lauer, S, Shing, M, Pivot, X, Koroveshi, D, Bouzid, K, Casalnuovo, M, Cascallar, D, Korbenfeld, E, Bastick, P, Beith, J, Colosimo, M, Friedlander, M, Ganju, V, Green, M, Patterson, K, Redfern, A, Richardson, G, Ceric, T, Gordana, K, Beato, C, Ferrari, M, Hegg, R, Helena, V, Ismael, G, Lessa, A, Mano, M, Morelle, A, Nogueira, J, Timcheva, K, Tomova, A, Tsakova, M, Zlatareva-Petrova, A, Asselah, J, Assi, H, Brezden-Masley, C, Chia, S, Freedman, O, Harb, M, Joy, A, Kulkarni, S, Prady, C, Gaete, A, Matamala, L, Torres, R, Yanez, E, Franco, S, Urrego, M, Gugic, D, Vrbanec, D, Melichar, B, Prausova, J, Vyzula, R, Pilarte, R, Leon, M, Munoz, R, Ramos, G, Azeem, H, Aziz, A, El Zawahry, H, Osegueda, F, Alexandre, J, Artignan, X, Barletta, H, Beguier, E, Berdah, J, Marty, C, Bollet, M, Bourgeois, H, Bressac, C, Burki, F, Campone, M, Coeffic, D, Cojocarasu, O, Dagada, C, Dalenc, F, Del Piano, F, Desauw, C, Desmoulins, I, Dohollou, N, Egreteau, J, Ferrero, J, Foa, C, Garidi, R, Gasnault, L, Guardiola, E, Hamizi, S, Jarcau, R, Jacquin, J, Jaubert, D, Jolimoy, G, Mineur, H, Largillier, R, Leduc, B, Martin, P, Melis, A, Monge, J, Moullet, I, Mousseau, M, Nguyen, S, Orfeuvre, H, Petit, T, Priou, F, Bach, I, Simon, H, Stefani, L, Uwer, L, Youssef, A, Aktas, B, von der Assen, A, Augustin, D, Balser, C, Bauer, L, Bechtner, C, Beyer, G, Brucker, C, Buckner, U, Busch, S, Christensen, B, Deryal, M, Farrokh, A, Faust, E, Friedrichs, K, Graf, H, Griesshammer, M, Grischke, E, Hanle, C, Heider, A, Henschen, S, Hesse, T, Jackisch, C, Kisro, J, Kohler, A, Kuemmel, S, Lampe, D, Lantzsch, T, Latos, K, Lex, B, Liedtke, C, Luedders, D, Maintz, C, Muller, V, Overkamp, F, Park-Simon, T, Paul, M, Prechtl, A, Ringsdorf, U, Runnebaum, I, Ruth, S, Salat, C, Scheffen, I, Schilling, J, Schmatloch, S, Schmidt, M, Schneeweiss, A, Schrader, I, Seipelt, G, Simon, E, Stefek, A, Stickeler, E, Thill, M, Tio, J, Tuczek, A, Warm, M, Weigel, M, Wischnik, A, Wojcinski, S, Ziegler-Lohr, K, Aravantinos, G, Ardavanis, A, Fountzilas, G, Gogas, H, Kakolyris, S, Mavroudis, D, Papadimitriou, C, Papandreou, C, Papazisis, K, Castro, H, Hernandez-Monroy, C, Ngan, R, Yeo, W, Bittner, N, Boer, K, Csejtei, A, Horvath, Z, Kocsis, J, Mangel, L, Mezei, K, Nagy, Z, Szanto, J, Atmakusuma, D, Fadjari, H, Kurnianda, D, Prayogo, N, Tanggo, E, Coate, L, Hennessy, B, Kelly, C, Martin, M, Nasim, S, O'Connor, M, Aieta, M, Allegrini, G, Amadori, D, Bidoli, P, Biti, G, Bordonaro, R, Bottini, A, Carterni, G, Cavanna, L, Cazzaniga, M, Cognetti, F, Contu, A, Cruciani, G, Donadio, M, Falcone, A, Farci, D, Forcignano, R, Frassoldati, A, Gaion, F, Gamucci, T, Giotta, F, Livi, L, Lorusso, V, Maiello, E, Marchetti, P, Mariani, G, Mion, M, Moscetti, L, Musolino, A, Pazzola, A, Pedrazzoli, P, Pigi, A, de Placido, S, Caremoli, E, Santoro, A, Tienghi, A, Ahn, J, Lee, K, Lee, S, Seo, J, Sohn, J, Cesas, A, Juozaityte, E, Cheah, N, Chong, F, Devi, B, Phua, V, Teoh, D, Ching, L, Yusof, M, Corona, J, Dominguez, A, Mendoza, R, Hernandez, C, Ramiro, A, Santos, J, Espinosa, P, Villarreal Garza, C, Errihani, H, Bakker, S, van den Berkmortel, F, Blaisse, R, Huinink, D, van den Bosch, J, Braun, J, Dercksen, M, Droogendijk, H, Erdkamp, F, Haringhuizen, A, de Jongh, F, Kok, T, Los, M, Madretsma, S, Terwogt, J, van der Padt, A, van Rossum-Schornagel, Q, Smilde, T, de Valk, B, van der Velden, A, van Warmerdam, L, van de Wouw, A, North, R, Kersten, C, Mjaaland, I, Wist, E, Aziz, Z, Masood, N, Rashid, K, Shah, M, Alcedo, J, Aleman, D, Neciosup, S, Reategui, R, Valdiviezo, N, Vera, L, Fernando, G, Roque, F, Strebel, H, Krzemieniecki, K, Litwiniuk, M, Mruk, A, Pienkowski, T, Sawrycki, P, Slomian, G, Tomczak, P, Afonso, N, Cardoso, F, Damasceno, M, Nave, M, Badulescu, F, Ciule, L, Curescu, S, Eniu, A, Filip, D, Grecea, D, Jinga, D, Lungulescu, D, Oprean, C, Stanculeanu, D, Turdean, M, Dvornichenko, V, Emelyanov, S, Lichinitser, M, Manikhas, A, Sakaeva, D, Shirinkin, V, Stroyakovskiy, D, Abulkhair, O, Zekri, J, Filipovic, S, Kovcin, V, Nedovic, J, Pesic, J, Vasovic, S, Ng, R, Bystricky, B, Leskova, J, Mardiak, J, Misurova, E, Wagnerova, M, Takac, I, Demetriou, G, Dreosti, L, Govender, P, Jordaan, J, Veersamy, P, Romero, J, Lopez, N, Arias, C, Chacon, J, Aramburo, A, Morales, L, Garcia, M, Estevez, L, Garcia-Palomo Perez, A, Garcia Saenz, J, Garcia Sanchis, L, Cubells, L, Cortijo, L, Santiago, S, De Aranguiz, B, Manas, J, Gallego, P, Cussac, A, Ferrandiz, C, Garrido, M, Alvarez, P, Vega, J, Del Prado, P, Janez, N, Murillo, S, Rosales, A, Jaso, L, Fernandez, I, Martorell, A, Carrion, R, Simon, S, Alcibar, A, Lorenzo, J, Garcia, V, Asensio, T, Maicas, M, Villanueva Silva, M, Killander, F, Svensson, J, Fehr, M, Hauser, N, Muller, A, Pagani, O, Passmann-Kegel, H, Popescu, R, Rabaglio, M, Rauch, D, Schlatter, C, Zaman, K, Chang, T, Huang, C, Wang, H, Yu, J, Bandidwattanawong, C, Maneechavakajorn, J, Seetalarom, K, Dejthevaporn, T, Somwangprasert, A, Vongsaisuwon, M, Akbulut, H, Altundag, K, Arican, A, Bozcuk, H, Eralp, Y, Idris, M, Isikdogan, A, Senol, C, Sevinc, A, Uygun, K, Yucel, E, Yucel, I, Yumuk, F, Shparyk, Y, Voitko, N, Jaloudi, M, Adams, J, Agrawal, R, Ahmed, S, Alhasso, A, Allerton, R, Anwar, S, Archer, C, Ashford, R, Barraclough, L, Bertelli, G, Bishop, J, Branson, T, Butt, M, Chakrabarti, A, Chakraborti, P, Churn, M, Crowley, C, Davis, R, Dhadda, A, Eldeeb, H, Fraser, J, Hall, J, Hickish, T, Hogg, M, Howe, T, Joffe, J, Kelleher, M, Kelly, S, Kendall, A, Kristeleit, H, Lumsden, G, Macmillan, C, Macpherson, I, Malik, Z, Mithal, N, Neal, A, Panwar, U, Proctor, A, Proctor, S, Raj, S, Rehman, S, Sandri, I, Scatchard, K, Sherwin, E, Sims, E, Singer, J, Smith, S, Tahir, S, Taylor, W, Tsalic, M, Wardley, A, Waters, S, Wheatley, D, Wright, K, Yuille, F, Alonso, I, Artagaveytia, N, Rodriguez, R, Arbona, E, Garcia, Y, Lion, L, Marcano, D, Van Thuan, T, Gligorov J., Ataseven B., Verrill M., de Laurentiis M., Jung K. H., Azim H. A., Al-Sakaff N., Lauer S., Shing M., Pivot X., Koroveshi D., Bouzid K., Casalnuovo M., Cascallar D., Korbenfeld E. P., Bastick P., Beith J., Colosimo M., Friedlander M., Ganju V., Green M., Patterson K., Redfern A., Richardson G., Ceric T., Gordana K., Beato C. A., Ferrari M., Hegg R., Helena V., Ismael G. F., Lessa A. E., Mano M., Morelle A., Nogueira J. A., Timcheva K., Tomova A., Tsakova M., Zlatareva-Petrova A., Asselah J., Assi H., Brezden-Masley C., Chia S., Freedman O., Harb M., Joy A. A., Kulkarni S., Prady C., Gaete A. A. A., Matamala L., Torres R., Yanez E., Franco S., Urrego M., Gugic D., Vrbanec D., Melichar B., Prausova J., Vyzula R., Pilarte R. G., Leon M. I., Munoz R., Ramos G., Azeem H. A., Aziz A. A., El Zawahry H., Osegueda F. R., Alexandre J., Artignan X., Barletta H., Beguier E., Berdah J. -F., Marty C. B., Bollet M., Bourgeois H., Bressac C., Burki F., Campone M., Coeffic D., Cojocarasu O. Z., Dagada C., Dalenc F., Del Piano F., Desauw C., Desmoulins I., Dohollou N., Egreteau J., Ferrero J. -M., Foa C., Garidi R., Gasnault L., Guardiola E., Hamizi S., Jarcau R., Jacquin J. -P., Jaubert D., Jolimoy G., Mineur H. L., Largillier R., Leduc B., Martin P., Melis A., Monge J., Moullet I., Mousseau M., Nguyen S., Orfeuvre H., Petit T., Priou F., Bach I. S., Simon H., Stefani L., Uwer L., Youssef A., Aktas B., von der Assen A., Augustin D., Balser C., Bauer L. -E., Bechtner C., Beyer G., Brucker C., Buckner U., Busch S., Christensen B., Deryal M., Farrokh A., Faust E., Friedrichs K., Graf H., Griesshammer M., Grischke E. -M., Hanle C., Heider A., Henschen S., Hesse T., Jackisch C., Kisro J., Kohler A., Kuemmel S., Lampe D., Lantzsch T., Latos K., Lex B., Liedtke C., Luedders D., Maintz C., Muller V., Overkamp F., Park-Simon T. -W., Paul M., Prechtl A., Ringsdorf U., Runnebaum I., Ruth S., Salat C., Scheffen I., Schilling J., Schmatloch S., Schmidt M., Schneeweiss A., Schrader I., Seipelt G., Simon E., Stefek A., Stickeler E., Thill M., Tio J., Tuczek A., Warm M., Weigel M., Wischnik A., Wojcinski S., Ziegler-Lohr K., Aravantinos G., Ardavanis A., Fountzilas G., Gogas H., Kakolyris S., Mavroudis D., Papadimitriou C., Papandreou C., Papazisis K., Castro H., Hernandez-Monroy C. E., Ngan R., Yeo W., Bittner N., Boer K., Csejtei A., Horvath Z., Kocsis J., Mangel L. C., Mezei K., Nagy Z., Szanto J., Atmakusuma D., Fadjari H., Kurnianda D., Prayogo N., Tanggo E. H., Coate L., Hennessy B., Kelly C., Martin M., Nasim S., O'Connor M., Aieta M., Allegrini G., Amadori D., Bidoli P., Biti G., Bordonaro R., Bottini A., Carterni G., Cavanna L., Cazzaniga M., Cognetti F., Contu A., Cruciani G., Donadio M., Falcone A., Farci D., Forcignano R. C., Frassoldati A., Gaion F., Gamucci T., Giotta F., Livi L., Lorusso V., Maiello E., Marchetti P., Mariani G., Mion M., Moscetti L., Musolino A., Pazzola A., Pedrazzoli P., Pigi A., de Placido S., Caremoli E. R., Santoro A., Tienghi A., Ahn J. -S., Lee K. S., Lee S. H., Seo J. H., Sohn J. -H., Cesas A., Juozaityte E., Cheah N. L. C., Chong F. L. T., Devi B. C. R., Phua V., Teoh D., Ching L. W., Yusof M., Corona J., Dominguez A., Mendoza R. L. G., Hernandez C. A., Ramiro A. J., Santos J. M., Espinosa P. M., Villarreal Garza C. M., Errihani H., Bakker S., van den Berkmortel F., Blaisse R. J. B., Huinink D. T. B., van den Bosch J., Braun J. J., Dercksen M. W., Droogendijk H., Erdkamp F., Haringhuizen A., de Jongh F. E., Kok T. C., Los M., Madretsma S., Terwogt J. M. M., van der Padt A., van Rossum-Schornagel Q. C., Smilde T. J., de Valk B., van der Velden A., van Warmerdam L., van de Wouw A. J., North R., Kersten C., Mjaaland I., Wist E., Aziz Z., Masood N., Rashid K., Shah M., Alcedo J. C., Aleman D., Neciosup S., Reategui R., Valdiviezo N., Vera L., Fernando G., Roque F., Strebel H. M., Krzemieniecki K., Litwiniuk M., Mruk A., Pienkowski T., Sawrycki P., Slomian G., Tomczak P., Afonso N., Cardoso F., Damasceno M., Nave M., Badulescu F., Ciule L., Curescu S., Eniu A., Filip D., Grecea D., Jinga D. -C., Lungulescu D., Oprean C. M., Stanculeanu D. L., Turdean M., Dvornichenko V., Emelyanov S., Lichinitser M., Manikhas A., Sakaeva D., Shirinkin V., Stroyakovskiy D., Abulkhair O., Zekri J., Filipovic S., Kovcin V., Nedovic J., Pesic J., Vasovic S., Ng R., Bystricky B., Leskova J., Mardiak J., Misurova E., Wagnerova M., Takac I., Demetriou G. S., Dreosti L., Govender P., Jordaan J. P., Veersamy P., Romero J. L. A., Lopez N. B., Arias C. C., Chacon J., Aramburo A. F., Morales L. A. F., Garcia M., Estevez L. G., Garcia-Palomo Perez A., Garcia Saenz J. A., Garcia Sanchis L., Cubells L. G., Cortijo L. G., Santiago S. G., De Aranguiz B. H. F., Manas J. J. I., Gallego P. J., Cussac A. L., Ferrandiz C. L., Garrido M. L., Alvarez P. L., Vega J. M. L., Del Prado P. M., Janez N. M., Murillo S. M., Rosales A. M., Jaso L. M., Fernandez I. P., Martorell A. P., Carrion R. P., Simon S. P., Alcibar A. P., Lorenzo J. P., Garcia V. Q., Asensio T. R. Y. C., Maicas M. D. T., Villanueva Silva M. J., Killander F., Svensson J. H., Fehr M., Hauser N., Muller A., Pagani O., Passmann-Kegel H., Popescu R., Rabaglio M., Rauch D., Schlatter C., Zaman K., Chang T. -W., Huang C. -S., Wang H. -C., Yu J. -C., Bandidwattanawong C., Maneechavakajorn J., Seetalarom K., Dejthevaporn T. S., Somwangprasert A., Vongsaisuwon M., Akbulut H., Altundag K., Arican A., Bozcuk H., Eralp Y., Idris M., Isikdogan A., Senol C. H., Sevinc A., Uygun K., Yucel E., Yucel I., Yumuk F., Shparyk Y., Voitko N., Jaloudi M., Adams J., Agrawal R., Ahmed S., Alhasso A., Allerton R., Anwar S., Archer C., Ashford R., Barraclough L., Bertelli G., Bishop J., Branson T., Butt M., Chakrabarti A., Chakraborti P., Churn M., Crowley C., Davis R., Dhadda A., Eldeeb H., Fraser J., Hall J., Hickish T., Hogg M., Howe T., Joffe J., Kelleher M., Kelly S., Kendall A., Kristeleit H., Lumsden G., Macmillan C., MacPherson I., Malik Z., Mithal N., Neal A., Panwar U., Proctor A., Proctor S. J., Raj S., Rehman S., Sandri I., Scatchard K., Sherwin E., Sims E., Singer J., Smith S., Tahir S., Taylor W., Tsalic M., Wardley A., Waters S., Wheatley D., Wright K., Yuille F., Alonso I., Artagaveytia N., Rodriguez R., Arbona E., Garcia Y., Lion L., Marcano D., Van Thuan T., Gligorov, J, Ataseven, B, Verrill, M, de Laurentiis, M, Jung, K, Azim, H, Al-Sakaff, N, Lauer, S, Shing, M, Pivot, X, Koroveshi, D, Bouzid, K, Casalnuovo, M, Cascallar, D, Korbenfeld, E, Bastick, P, Beith, J, Colosimo, M, Friedlander, M, Ganju, V, Green, M, Patterson, K, Redfern, A, Richardson, G, Ceric, T, Gordana, K, Beato, C, Ferrari, M, Hegg, R, Helena, V, Ismael, G, Lessa, A, Mano, M, Morelle, A, Nogueira, J, Timcheva, K, Tomova, A, Tsakova, M, Zlatareva-Petrova, A, Asselah, J, Assi, H, Brezden-Masley, C, Chia, S, Freedman, O, Harb, M, Joy, A, Kulkarni, S, Prady, C, Gaete, A, Matamala, L, Torres, R, Yanez, E, Franco, S, Urrego, M, Gugic, D, Vrbanec, D, Melichar, B, Prausova, J, Vyzula, R, Pilarte, R, Leon, M, Munoz, R, Ramos, G, Azeem, H, Aziz, A, El Zawahry, H, Osegueda, F, Alexandre, J, Artignan, X, Barletta, H, Beguier, E, Berdah, J, Marty, C, Bollet, M, Bourgeois, H, Bressac, C, Burki, F, Campone, M, Coeffic, D, Cojocarasu, O, Dagada, C, Dalenc, F, Del Piano, F, Desauw, C, Desmoulins, I, Dohollou, N, Egreteau, J, Ferrero, J, Foa, C, Garidi, R, Gasnault, L, Guardiola, E, Hamizi, S, Jarcau, R, Jacquin, J, Jaubert, D, Jolimoy, G, Mineur, H, Largillier, R, Leduc, B, Martin, P, Melis, A, Monge, J, Moullet, I, Mousseau, M, Nguyen, S, Orfeuvre, H, Petit, T, Priou, F, Bach, I, Simon, H, Stefani, L, Uwer, L, Youssef, A, Aktas, B, von der Assen, A, Augustin, D, Balser, C, Bauer, L, Bechtner, C, Beyer, G, Brucker, C, Buckner, U, Busch, S, Christensen, B, Deryal, M, Farrokh, A, Faust, E, Friedrichs, K, Graf, H, Griesshammer, M, Grischke, E, Hanle, C, Heider, A, Henschen, S, Hesse, T, Jackisch, C, Kisro, J, Kohler, A, Kuemmel, S, Lampe, D, Lantzsch, T, Latos, K, Lex, B, Liedtke, C, Luedders, D, Maintz, C, Muller, V, Overkamp, F, Park-Simon, T, Paul, M, Prechtl, A, Ringsdorf, U, Runnebaum, I, Ruth, S, Salat, C, Scheffen, I, Schilling, J, Schmatloch, S, Schmidt, M, Schneeweiss, A, Schrader, I, Seipelt, G, Simon, E, Stefek, A, Stickeler, E, Thill, M, Tio, J, Tuczek, A, Warm, M, Weigel, M, Wischnik, A, Wojcinski, S, Ziegler-Lohr, K, Aravantinos, G, Ardavanis, A, Fountzilas, G, Gogas, H, Kakolyris, S, Mavroudis, D, Papadimitriou, C, Papandreou, C, Papazisis, K, Castro, H, Hernandez-Monroy, C, Ngan, R, Yeo, W, Bittner, N, Boer, K, Csejtei, A, Horvath, Z, Kocsis, J, Mangel, L, Mezei, K, Nagy, Z, Szanto, J, Atmakusuma, D, Fadjari, H, Kurnianda, D, Prayogo, N, Tanggo, E, Coate, L, Hennessy, B, Kelly, C, Martin, M, Nasim, S, O'Connor, M, Aieta, M, Allegrini, G, Amadori, D, Bidoli, P, Biti, G, Bordonaro, R, Bottini, A, Carterni, G, Cavanna, L, Cazzaniga, M, Cognetti, F, Contu, A, Cruciani, G, Donadio, M, Falcone, A, Farci, D, Forcignano, R, Frassoldati, A, Gaion, F, Gamucci, T, Giotta, F, Livi, L, Lorusso, V, Maiello, E, Marchetti, P, Mariani, G, Mion, M, Moscetti, L, Musolino, A, Pazzola, A, Pedrazzoli, P, Pigi, A, de Placido, S, Caremoli, E, Santoro, A, Tienghi, A, Ahn, J, Lee, K, Lee, S, Seo, J, Sohn, J, Cesas, A, Juozaityte, E, Cheah, N, Chong, F, Devi, B, Phua, V, Teoh, D, Ching, L, Yusof, M, Corona, J, Dominguez, A, Mendoza, R, Hernandez, C, Ramiro, A, Santos, J, Espinosa, P, Villarreal Garza, C, Errihani, H, Bakker, S, van den Berkmortel, F, Blaisse, R, Huinink, D, van den Bosch, J, Braun, J, Dercksen, M, Droogendijk, H, Erdkamp, F, Haringhuizen, A, de Jongh, F, Kok, T, Los, M, Madretsma, S, Terwogt, J, van der Padt, A, van Rossum-Schornagel, Q, Smilde, T, de Valk, B, van der Velden, A, van Warmerdam, L, van de Wouw, A, North, R, Kersten, C, Mjaaland, I, Wist, E, Aziz, Z, Masood, N, Rashid, K, Shah, M, Alcedo, J, Aleman, D, Neciosup, S, Reategui, R, Valdiviezo, N, Vera, L, Fernando, G, Roque, F, Strebel, H, Krzemieniecki, K, Litwiniuk, M, Mruk, A, Pienkowski, T, Sawrycki, P, Slomian, G, Tomczak, P, Afonso, N, Cardoso, F, Damasceno, M, Nave, M, Badulescu, F, Ciule, L, Curescu, S, Eniu, A, Filip, D, Grecea, D, Jinga, D, Lungulescu, D, Oprean, C, Stanculeanu, D, Turdean, M, Dvornichenko, V, Emelyanov, S, Lichinitser, M, Manikhas, A, Sakaeva, D, Shirinkin, V, Stroyakovskiy, D, Abulkhair, O, Zekri, J, Filipovic, S, Kovcin, V, Nedovic, J, Pesic, J, Vasovic, S, Ng, R, Bystricky, B, Leskova, J, Mardiak, J, Misurova, E, Wagnerova, M, Takac, I, Demetriou, G, Dreosti, L, Govender, P, Jordaan, J, Veersamy, P, Romero, J, Lopez, N, Arias, C, Chacon, J, Aramburo, A, Morales, L, Garcia, M, Estevez, L, Garcia-Palomo Perez, A, Garcia Saenz, J, Garcia Sanchis, L, Cubells, L, Cortijo, L, Santiago, S, De Aranguiz, B, Manas, J, Gallego, P, Cussac, A, Ferrandiz, C, Garrido, M, Alvarez, P, Vega, J, Del Prado, P, Janez, N, Murillo, S, Rosales, A, Jaso, L, Fernandez, I, Martorell, A, Carrion, R, Simon, S, Alcibar, A, Lorenzo, J, Garcia, V, Asensio, T, Maicas, M, Villanueva Silva, M, Killander, F, Svensson, J, Fehr, M, Hauser, N, Muller, A, Pagani, O, Passmann-Kegel, H, Popescu, R, Rabaglio, M, Rauch, D, Schlatter, C, Zaman, K, Chang, T, Huang, C, Wang, H, Yu, J, Bandidwattanawong, C, Maneechavakajorn, J, Seetalarom, K, Dejthevaporn, T, Somwangprasert, A, Vongsaisuwon, M, Akbulut, H, Altundag, K, Arican, A, Bozcuk, H, Eralp, Y, Idris, M, Isikdogan, A, Senol, C, Sevinc, A, Uygun, K, Yucel, E, Yucel, I, Yumuk, F, Shparyk, Y, Voitko, N, Jaloudi, M, Adams, J, Agrawal, R, Ahmed, S, Alhasso, A, Allerton, R, Anwar, S, Archer, C, Ashford, R, Barraclough, L, Bertelli, G, Bishop, J, Branson, T, Butt, M, Chakrabarti, A, Chakraborti, P, Churn, M, Crowley, C, Davis, R, Dhadda, A, Eldeeb, H, Fraser, J, Hall, J, Hickish, T, Hogg, M, Howe, T, Joffe, J, Kelleher, M, Kelly, S, Kendall, A, Kristeleit, H, Lumsden, G, Macmillan, C, Macpherson, I, Malik, Z, Mithal, N, Neal, A, Panwar, U, Proctor, A, Proctor, S, Raj, S, Rehman, S, Sandri, I, Scatchard, K, Sherwin, E, Sims, E, Singer, J, Smith, S, Tahir, S, Taylor, W, Tsalic, M, Wardley, A, Waters, S, Wheatley, D, Wright, K, Yuille, F, Alonso, I, Artagaveytia, N, Rodriguez, R, Arbona, E, Garcia, Y, Lion, L, Marcano, D, Van Thuan, T, Gligorov J., Ataseven B., Verrill M., de Laurentiis M., Jung K. H., Azim H. A., Al-Sakaff N., Lauer S., Shing M., Pivot X., Koroveshi D., Bouzid K., Casalnuovo M., Cascallar D., Korbenfeld E. P., Bastick P., Beith J., Colosimo M., Friedlander M., Ganju V., Green M., Patterson K., Redfern A., Richardson G., Ceric T., Gordana K., Beato C. A., Ferrari M., Hegg R., Helena V., Ismael G. F., Lessa A. E., Mano M., Morelle A., Nogueira J. A., Timcheva K., Tomova A., Tsakova M., Zlatareva-Petrova A., Asselah J., Assi H., Brezden-Masley C., Chia S., Freedman O., Harb M., Joy A. A., Kulkarni S., Prady C., Gaete A. A. A., Matamala L., Torres R., Yanez E., Franco S., Urrego M., Gugic D., Vrbanec D., Melichar B., Prausova J., Vyzula R., Pilarte R. G., Leon M. I., Munoz R., Ramos G., Azeem H. A., Aziz A. A., El Zawahry H., Osegueda F. R., Alexandre J., Artignan X., Barletta H., Beguier E., Berdah J. -F., Marty C. B., Bollet M., Bourgeois H., Bressac C., Burki F., Campone M., Coeffic D., Cojocarasu O. Z., Dagada C., Dalenc F., Del Piano F., Desauw C., Desmoulins I., Dohollou N., Egreteau J., Ferrero J. -M., Foa C., Garidi R., Gasnault L., Guardiola E., Hamizi S., Jarcau R., Jacquin J. -P., Jaubert D., Jolimoy G., Mineur H. L., Largillier R., Leduc B., Martin P., Melis A., Monge J., Moullet I., Mousseau M., Nguyen S., Orfeuvre H., Petit T., Priou F., Bach I. S., Simon H., Stefani L., Uwer L., Youssef A., Aktas B., von der Assen A., Augustin D., Balser C., Bauer L. -E., Bechtner C., Beyer G., Brucker C., Buckner U., Busch S., Christensen B., Deryal M., Farrokh A., Faust E., Friedrichs K., Graf H., Griesshammer M., Grischke E. -M., Hanle C., Heider A., Henschen S., Hesse T., Jackisch C., Kisro J., Kohler A., Kuemmel S., Lampe D., Lantzsch T., Latos K., Lex B., Liedtke C., Luedders D., Maintz C., Muller V., Overkamp F., Park-Simon T. -W., Paul M., Prechtl A., Ringsdorf U., Runnebaum I., Ruth S., Salat C., Scheffen I., Schilling J., Schmatloch S., Schmidt M., Schneeweiss A., Schrader I., Seipelt G., Simon E., Stefek A., Stickeler E., Thill M., Tio J., Tuczek A., Warm M., Weigel M., Wischnik A., Wojcinski S., Ziegler-Lohr K., Aravantinos G., Ardavanis A., Fountzilas G., Gogas H., Kakolyris S., Mavroudis D., Papadimitriou C., Papandreou C., Papazisis K., Castro H., Hernandez-Monroy C. E., Ngan R., Yeo W., Bittner N., Boer K., Csejtei A., Horvath Z., Kocsis J., Mangel L. C., Mezei K., Nagy Z., Szanto J., Atmakusuma D., Fadjari H., Kurnianda D., Prayogo N., Tanggo E. H., Coate L., Hennessy B., Kelly C., Martin M., Nasim S., O'Connor M., Aieta M., Allegrini G., Amadori D., Bidoli P., Biti G., Bordonaro R., Bottini A., Carterni G., Cavanna L., Cazzaniga M., Cognetti F., Contu A., Cruciani G., Donadio M., Falcone A., Farci D., Forcignano R. C., Frassoldati A., Gaion F., Gamucci T., Giotta F., Livi L., Lorusso V., Maiello E., Marchetti P., Mariani G., Mion M., Moscetti L., Musolino A., Pazzola A., Pedrazzoli P., Pigi A., de Placido S., Caremoli E. R., Santoro A., Tienghi A., Ahn J. -S., Lee K. S., Lee S. H., Seo J. H., Sohn J. -H., Cesas A., Juozaityte E., Cheah N. L. C., Chong F. L. T., Devi B. C. R., Phua V., Teoh D., Ching L. W., Yusof M., Corona J., Dominguez A., Mendoza R. L. G., Hernandez C. A., Ramiro A. J., Santos J. M., Espinosa P. M., Villarreal Garza C. M., Errihani H., Bakker S., van den Berkmortel F., Blaisse R. J. B., Huinink D. T. B., van den Bosch J., Braun J. J., Dercksen M. W., Droogendijk H., Erdkamp F., Haringhuizen A., de Jongh F. E., Kok T. C., Los M., Madretsma S., Terwogt J. M. M., van der Padt A., van Rossum-Schornagel Q. C., Smilde T. J., de Valk B., van der Velden A., van Warmerdam L., van de Wouw A. J., North R., Kersten C., Mjaaland I., Wist E., Aziz Z., Masood N., Rashid K., Shah M., Alcedo J. C., Aleman D., Neciosup S., Reategui R., Valdiviezo N., Vera L., Fernando G., Roque F., Strebel H. M., Krzemieniecki K., Litwiniuk M., Mruk A., Pienkowski T., Sawrycki P., Slomian G., Tomczak P., Afonso N., Cardoso F., Damasceno M., Nave M., Badulescu F., Ciule L., Curescu S., Eniu A., Filip D., Grecea D., Jinga D. -C., Lungulescu D., Oprean C. M., Stanculeanu D. L., Turdean M., Dvornichenko V., Emelyanov S., Lichinitser M., Manikhas A., Sakaeva D., Shirinkin V., Stroyakovskiy D., Abulkhair O., Zekri J., Filipovic S., Kovcin V., Nedovic J., Pesic J., Vasovic S., Ng R., Bystricky B., Leskova J., Mardiak J., Misurova E., Wagnerova M., Takac I., Demetriou G. S., Dreosti L., Govender P., Jordaan J. P., Veersamy P., Romero J. L. A., Lopez N. B., Arias C. C., Chacon J., Aramburo A. F., Morales L. A. F., Garcia M., Estevez L. G., Garcia-Palomo Perez A., Garcia Saenz J. A., Garcia Sanchis L., Cubells L. G., Cortijo L. G., Santiago S. G., De Aranguiz B. H. F., Manas J. J. I., Gallego P. J., Cussac A. L., Ferrandiz C. L., Garrido M. L., Alvarez P. L., Vega J. M. L., Del Prado P. M., Janez N. M., Murillo S. M., Rosales A. M., Jaso L. M., Fernandez I. P., Martorell A. P., Carrion R. P., Simon S. P., Alcibar A. P., Lorenzo J. P., Garcia V. Q., Asensio T. R. Y. C., Maicas M. D. T., Villanueva Silva M. J., Killander F., Svensson J. H., Fehr M., Hauser N., Muller A., Pagani O., Passmann-Kegel H., Popescu R., Rabaglio M., Rauch D., Schlatter C., Zaman K., Chang T. -W., Huang C. -S., Wang H. -C., Yu J. -C., Bandidwattanawong C., Maneechavakajorn J., Seetalarom K., Dejthevaporn T. S., Somwangprasert A., Vongsaisuwon M., Akbulut H., Altundag K., Arican A., Bozcuk H., Eralp Y., Idris M., Isikdogan A., Senol C. H., Sevinc A., Uygun K., Yucel E., Yucel I., Yumuk F., Shparyk Y., Voitko N., Jaloudi M., Adams J., Agrawal R., Ahmed S., Alhasso A., Allerton R., Anwar S., Archer C., Ashford R., Barraclough L., Bertelli G., Bishop J., Branson T., Butt M., Chakrabarti A., Chakraborti P., Churn M., Crowley C., Davis R., Dhadda A., Eldeeb H., Fraser J., Hall J., Hickish T., Hogg M., Howe T., Joffe J., Kelleher M., Kelly S., Kendall A., Kristeleit H., Lumsden G., Macmillan C., MacPherson I., Malik Z., Mithal N., Neal A., Panwar U., Proctor A., Proctor S. J., Raj S., Rehman S., Sandri I., Scatchard K., Sherwin E., Sims E., Singer J., Smith S., Tahir S., Taylor W., Tsalic M., Wardley A., Waters S., Wheatley D., Wright K., Yuille F., Alonso I., Artagaveytia N., Rodriguez R., Arbona E., Garcia Y., Lion L., Marcano D., and Van Thuan T.
- Abstract
Aim To assess the safety and tolerability of adjuvant subcutaneous trastuzumab (Herceptin® SC, H SC), delivered from an H SC Vial via hand-held syringe (Cohort A) or single-use injection device (Cohort B), with or without chemotherapy, for human epidermal growth factor receptor 2 (HER2)-positive stage I to IIIC early breast cancer (EBC) in the phase III SafeHer study (NCT01566721). Methods Patients received 600 mg fixed-dose H SC every 3 weeks for 18 cycles. The chemotherapy partner was at the investigators' discretion (H SC monotherapy was limited to ≤10% of the population). Data from the first H SC dose until 28 days (plus a 5-day window) after the last dose are presented. Results are descriptive. Results In the overall population, 2282/2573 patients (88.7%) experienced adverse events (AEs). Of the above, 128 (5.0%) patients experienced AEs leading to study drug discontinuation; 596 (23.2%) experienced grade ≥ 3 AEs and 326 (12.7%) experienced serious AEs. Grade ≥ 3 cardiac disorders were reported in 24 patients (0.9%), including congestive heart failure in eight (0.3%). As expected, the AE rates varied according to the timing of chemotherapy in both cohorts, with higher rates in concurrent versus sequential chemotherapy subgroups. In the concurrent chemotherapy subgroup, AEs were more common during the actual period of concurrent chemotherapy compared with the period when patients did not receive concurrent chemotherapy. Conclusion SafeHer confirms the safety and tolerability of the H SC 600 mg fixed dose for 1 year (every 3 weeks for 18 cycles) as adjuvant therapy with concurrent or sequential chemotherapy for HER2-positive EBC. These primary analysis results are consistent with the known safety profile for intravenous H and H SC.
- Published
- 2017
22. Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study
- Author
-
Pronzato, P, Mustacchi, G, Riccardi, F, Turletti, A, Michelotti, A, Natoli, C, Livi, L, Del Mastro, L, Donadio, M, Garrone, O, Giordano, M, De Laurentiis, M, Marchetti, P, Montemurro, F, Romagnoli, E, De Placido, S, Biganzoli, L, Cazzaniga, M, Pronzato P., Mustacchi G., Riccardi F., Turletti A., Michelotti A., Natoli C., Livi L., Del Mastro L., Donadio M., Garrone O., Giordano M., De Laurentiis M., Marchetti P., Montemurro F., Romagnoli E., De Placido S., Biganzoli L., Cazzaniga M., Pronzato, P, Mustacchi, G, Riccardi, F, Turletti, A, Michelotti, A, Natoli, C, Livi, L, Del Mastro, L, Donadio, M, Garrone, O, Giordano, M, De Laurentiis, M, Marchetti, P, Montemurro, F, Romagnoli, E, De Placido, S, Biganzoli, L, Cazzaniga, M, Pronzato P., Mustacchi G., Riccardi F., Turletti A., Michelotti A., Natoli C., Livi L., Del Mastro L., Donadio M., Garrone O., Giordano M., De Laurentiis M., Marchetti P., Montemurro F., Romagnoli E., De Placido S., Biganzoli L., and Cazzaniga M.
- Published
- 2017
23. Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma
- Author
-
Katsaros, D., Oletti, M.V., Rigault de la Longrais, I.A., Ferrero, A., Celano, A., Fracchioli, S., Donadio, M., Passera, R., Cattel, L., and Bumma, C.
- Published
- 2005
- Full Text
- View/download PDF
24. THE BORG SCALE IS ACCURATE IN ADOLESCENTS AND CHILDREN OVER THE AGE OF NINE WITH CYSTIC FIBROSIS: 529
- Author
-
Hommerding, P. X., Donadio, M. F., Paim, T. F., and Marostica, P. C.
- Published
- 2008
25. Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin® are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study
- Author
-
Sapino, A., Montemurro, F., Marchiò, C., Viale, G., Kulka, J., Donadio, M., Bottini, A., Botti, G., dei Tos, A. P., Bersiga, A., Di Palma, S., Truini, M., Sanna, G., Aglietta, M., and Bussolati, G.
- Published
- 2007
26. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?
- Author
-
Ardine, M., Generali, D., Donadio, M., Bonardi, S., Scoletta, M., Vandone, A. M., Mozzati, M., Bertetto, O., Bottini, A., Dogliotti, L., and Berruti, A.
- Published
- 2006
27. Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?
- Author
-
Cazzaniga, M, Biganzoli, L, Cortesi, L, De Placido, S, Donadio, M, Fabi, A, Ferro, A, Generali, D, Lorusso, V, Milani, A, Montagna, E, Munzone, E, Orlando, L, Pizzuti, L, Simoncini, E, Zamagni, C, Pappagallo, G, Cazzaniga, Marina Elena, Biganzoli, Laura, Cortesi, Laura, De Placido, Sabino, Donadio, Michela, Fabi, Alessandra, Ferro, Antonella, Generali, Daniele, Lorusso, Vito, Milani, Andrea, Montagna, Emilia, Munzone, Elisabetta, Orlando, Laura, Pizzuti, Laura, Simoncini, Edda, Zamagni, Claudio, Pappagallo, Giovanni L, Cazzaniga, M, Biganzoli, L, Cortesi, L, De Placido, S, Donadio, M, Fabi, A, Ferro, A, Generali, D, Lorusso, V, Milani, A, Montagna, E, Munzone, E, Orlando, L, Pizzuti, L, Simoncini, E, Zamagni, C, Pappagallo, G, Cazzaniga, Marina Elena, Biganzoli, Laura, Cortesi, Laura, De Placido, Sabino, Donadio, Michela, Fabi, Alessandra, Ferro, Antonella, Generali, Daniele, Lorusso, Vito, Milani, Andrea, Montagna, Emilia, Munzone, Elisabetta, Orlando, Laura, Pizzuti, Laura, Simoncini, Edda, Zamagni, Claudio, and Pappagallo, Giovanni L
- Abstract
The prognosis for patients with locally advanced or metastatic breast cancer (mBC) remains poor, with a median survival of 2-4 years. About 10% of newly diagnosed breast cancer patients present with metastatic disease, and 30%-50% of those diagnosed at earlier stages will subsequently progress to mBC. In terms o f ongoing management for advanced/metastatic breast cancer after failure of hormonal therapy, there is a high medical need for new treatment options that prolong the interval to the start of intensive cytotoxic therapy, which is often associated with potentially serious side effects and reduced quality of life. Oral chemotherapeutic agents such as capecitabine and vinorelbine have demonstrated efficacy in patients with mBC, with prolonged disease control and good tolerability. Use of oral chemotherapy reduces the time and cost associated with treatment and is often more acceptable to patients than intravenous drug delivery. Metronomic administration of oral chemotherapy is therefore a promising treatment strategy for some patients with mBC and inhibits tumor progression via multiple mechanisms of action. Ongoing clinical trials are investigating metronomic chemotherapy regimens as a strategy to prolong disease control with favorable tolerability. This article provides an overview of metronomic chemotherapy treatment options in mBC, with perspectives on this therapy from a panel of experts.
- Published
- 2019
28. A PHASE II STUDY: TRASTUZUMAB (T) AND VINORELBINE (V) AS FIRST/SECOND LINE IN HER-2 OVEREXPRESSING METASTATIC BREAST CANCER (MBC)
- Author
-
Donadio, M., Coccorullo, Z., Ardine, M., Mistrangelo, M., Beano, A., Manzin, E., Garrone, O., and Bertetto, O.
- Published
- 2003
29. Multimodal treatment with primary single-agent epirubicin in operable breast cancer: 5-year experience of the Michelangelo Cooperative Group†
- Author
-
Bonadonna, G., Zambetti, M., Bumma, C., Donadio, M., Bolognesi, A., Robustellidella Cuna, G., Ambrosini, G., Lelli, G., Mansutti, M., Verderio, P., and Valagussa, P.
- Published
- 2002
30. GEMCITABINE AND 5-FLUOROURACILE IN THE TREATMENT OF ADVANCED PANCREATIC AND BILIARY TRACT CARCINOMA
- Author
-
Novarino, A, Durando, R, Donadio, M, Icardi, M, Ritorto, G, Occelli, M, Buffoni, L, Addeo, A, Robecchi, A, and Bertetto, O
- Published
- 2000
31. THE DIAGNOSTIC INFORMATION: A COMPARISON BETWEEN HOSPITAL DOCTORS AND GENERAL PRACTITIONERS.
- Author
-
Ritorto, G, Donadio, M, Coccorullo, Z, Occelli, M, Buffoni, L, Birocco, N, Lovera, G, and Bertetto, O
- Published
- 2000
32. DIAGNOSTIC INFORMATION IN ONCOLOGY: PRELIMINARY DATA FROM A SURVEY IN PIEDMONT.
- Author
-
Donadio, M, Coccorullo, Z, Birocco, N, Buffoni, L, Occelli, M, Ritorto, G, Lovera, G, and Bertetto, O
- Published
- 2000
33. 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
- Author
-
Conte, P, Frassoldati, A, Bisagni, G, Brandes, Aa, Donadio, M, Garrone, O, Piacentini, F, Cavanna, L, Giotta, F, Aieta, M, Gebbia, V, Molino, A, Musolino, A, Ferro, A, Maltoni, R, Danese, S, Zamagni, C, Rimanti, A, Cagossi, K, Russo, A, Pronzato, P, Giovanardi, F, Moretti, G, Lombardo, L, Schirone, A, Beano, A, Amaducci, L, Bajardi, Ea, Vicini, R, Balduzzi, Sara, D'Amico, R, and Guarneri, Valentina
- Subjects
trastuzumab ,breast cancer ,trastuzumab, adjuvant, breast cancer, cardiac safety, de-escalated treatment ,adjuvant ,cardiac safety ,de-escalated treatment - Published
- 2018
34. Changes in hormone-receptor status in luminal breast cancers between primary tumour and metastases: Results of the observational cohort GIM-13 AMBRA study
- Author
-
Cazzaniga, M.E., primary, Pronzato, P., additional, Del Mastro, L., additional, Natoli, C., additional, Montemurro, F., additional, Bisagni, G., additional, Blasi, L., additional, Turletti, A., additional, Giordano, M., additional, Biganzoli, L., additional, Michelotti, A., additional, Garrone, O., additional, Marchetti, P., additional, Riccardi, F., additional, Bernardo, A., additional, Livi, L., additional, Cognetti, F., additional, Donadio, M., additional, Romagnoli, E., additional, and Mustacchi, G., additional
- Published
- 2019
- Full Text
- View/download PDF
35. P1.11-38 Frequency and Prognostic Impact of Concomitant Mutations in KRAS and TP53 or STK11 in Brazilian Lung Adenocarcinoma Patients
- Author
-
De Sa, V., primary, Chinoca, J., additional, Spina Donadio, M., additional, De Lima, V., additional, Torrezan, G., additional, Carraro, D., additional, and Freitas, H., additional
- Published
- 2019
- Full Text
- View/download PDF
36. Validation of the American Joint Committee on Cancer new prognostic stage groups for HER2-positive breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the prospective ShortHER trial
- Author
-
Dieci, M.V., primary, Bisagni, G., additional, Brandes, A.A., additional, Frassoldati, A., additional, Donadio, M., additional, Garrone, O., additional, Piacentini, F., additional, Balduzzi, S., additional, Guarneri, V., additional, and Conte, P.F., additional
- Published
- 2019
- Full Text
- View/download PDF
37. Abstract GS3-01: A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ
- Author
-
DeCensi, A, primary, Puntoni, M, additional, Guerrieri Gonzaga, A, additional, Avino, F, additional, Cortesi, L, additional, Donadio, M, additional, Pacquola, M, additional, Falcini, F, additional, Gulisano, M, additional, Digennaro, M, additional, Tienghi, A, additional, Cagossi, K, additional, Pinotti, G, additional, Varicchio, C, additional, Caviglia, S, additional, Boni, L, additional, and Bonanni, B, additional
- Published
- 2019
- Full Text
- View/download PDF
38. Abstract P4-13-04: Not presented
- Author
-
Cazzaniga, ME, primary, Blasi, L, additional, Pronzato, P, additional, Giordano, M, additional, Garrone, O, additional, Donadio, M, additional, Del Mastro, L, additional, Livi, L, additional, Natoli, C, additional, Michelotti, A, additional, Turletti, A, additional, Riccardi, F, additional, De Laurentiis, M, additional, Marchetti, P, additional, Montemurro, F, additional, Romagnoli, E, additional, De Placido, S, additional, Biganzoli, L, additional, Bologna, A, additional, Bria, E, additional, and Mustacchi, G, additional
- Published
- 2019
- Full Text
- View/download PDF
39. 3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer
- Author
-
Conte, P, Bisagni, G, Frassoldati, A, Brandes, A, Cavanna, L, Giotta, F, Aieta, M, Gebbia, V, Musolino, A, Garrone, O, Donadio, M, Cavazzini, G, Turletti, A, Zamagni, C, Danese, S, Ferro, A, Piacentini, F, Balduzzi, S, D'Amico, R, and Guarneri, V
- Subjects
trastuzumab ,breast cancer ,immunologic adjuvants ,pharmaceutical adjuvants ,trastuzumab, immunologic adjuvants, pharmaceutical adjuvants, breast cancer - Published
- 2017
40. Abstract P1-13-02: Withdrawn
- Author
-
Guarneri, V, primary, Dieci, MV, additional, Bisagni, G, additional, Brandes, AA, additional, Frassoldati, A, additional, Cavanna, L, additional, Musolino, A, additional, Giotta, F, additional, Cavazzini, G, additional, Garrone, O, additional, Bertone, E, additional, Cagossi, K, additional, Nanni, O, additional, Ferro, A, additional, Donadio, M, additional, Aieta, M, additional, Zamagni, C, additional, Piacentini, F, additional, Maiorana, A, additional, Ragazzi, M, additional, Cucchi, MC, additional, Querzoli, P, additional, Orsi, N, additional, Curtarello, M, additional, Urso, L, additional, Amadori, A, additional, Orvieto, E, additional, Vicini, R, additional, Balduzzi, S, additional, D'Amico, R, additional, and Conte, P, additional
- Published
- 2018
- Full Text
- View/download PDF
41. Abstract P5-21-29: Moving from the CLEOPATRA study to real life: Preliminary results from the G.O.N.O. SUPER trial
- Author
-
Garrone, O, primary, D'Onofrio, L, additional, Blondeaux, E, additional, Bertolini, I, additional, Giarratano, T, additional, Beano, A, additional, Saggia, C, additional, Cazzaniga, M, additional, LaVerde, N, additional, Collovà, E, additional, Milani, A, additional, De Conciliis, E, additional, Coltelli, L, additional, Airoldi, M, additional, Del Mastro, L, additional, Cursano, MC, additional, Michelotti, A, additional, Vandone, AM, additional, Guarneri, V, additional, Donadio, M, additional, Riva, F, additional, Nuzzo, A, additional, and Merlano, MC, additional
- Published
- 2018
- Full Text
- View/download PDF
42. Effect of Intra- and Extrauterine Growth on Long-Term Neurologic Outcomes of Very Preterm Infants
- Author
-
Guellec, Isabelle, Lapillonne, Alexandre, Picaud, Jean-Charles, Mitanchez, Delphine, Charkaluk, Marie-Laure, Flamand, Cyril, Roze, Jean-Christophe, Ancel, Pierre-Yves, Larroque, Benoit, Ancel, P.Y., Blondel, B., Bréart, G., Garel, M., Kaminski, Monique, Maillard, F., du Mazaubrun, C., Missy, P., Sehili, F., Supernant, K., Marchand, L., Durand, M., Matis, J., Messer, J., Treisser, A., Burguet, A., Abraham-Lerat, L., Menget, A., Roth, P., Schaal, P., Thiriez, G., Leveque, C., Marret, Stéphane, Marpeau, L., Boulot, P., Cambonie, Gilles, Picaud, C., Donadio, M., Ledésert, B., André, M., Fresson, Jeanne, Hascoët, M., Arnaud, Catherine, Grandjean, H., Rolland, M., Fily, A., Ego, Anne, Outtier, M., Pierrat, V., Subtil, D., Truffert, P., Boog, G., Rouger-Bureau, V., Rozé, C., Dehan, M., Zupan-Simunek, V., Vodovar, M., Voyer, M., Equipe 1 : EPOPé - Épidémiologie Obstétricale, Périnatale et Pédiatrique (CRESS - U1153), Université Paris Descartes - Paris 5 (UPD5)-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Necker - Enfants Malades [AP-HP], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), CHU Trousseau [APHP], Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Périnatologie, Hôpital Mère Enfant, Recherches épidémiologiques en santé périnatale et santé des femmes, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Faculté des Sciences du SportFaculté des Sciences du Sport, UFR STAPS, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Rouen, Normandie Université (NU), Service de Gynécologie-Obstétrique et Médecine de la Reproduction [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Cergy Pontoise (UCP), Université Paris-Seine, Swedish Institute of Space Physics [Uppsala] (IRF), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), DGA Tech. Navales, DGA Tech.Navales, Service de Médecine Néonatale, Hôpital Jeanne de Flandre [Lille], Techniques pour l'Evaluation et la Modélisation des Actions de la Santé (TIMC-IMAG-ThEMAS), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Département d'obstétrique[Lille], Hôpital Jeanne de Flandre [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Biologie et physiologie des cellules digestives, Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de recherche clinique intersectorielle du Centre Hospitalier Henri Laborit, Centre Hospitalier Henri Laborit (CHL), Faculté des Sciences du SportFaculté des Sciences du Sport, UFR STAPS-Université Blaise Pascal - Clermont-Ferrand 2 (UBP), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université, Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-UFR Sciences et Techniques des Activités Physiques et Sportives - Clermont-Ferrand (UFR STAPS - UBP), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Techniques pour l'Evaluation et la Modélisation des Actions de la Santé (TIMC-ThEMAS), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-IMAG-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-IMAG-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA), and Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])
- Subjects
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2016
43. Importance of adherence to guidelines in breast cancer clinical practice. The Italian experience (AIOM)
- Author
-
Barni, S., Venturini, M., Molino, A., Donadio, M., Rizzoli, S., Maiello, E., and Stefania Gori
- Subjects
Adult ,Male ,Cancer Research ,Breast Neoplasms ,General Medicine ,Cancer Care Facilities ,Middle Aged ,Medical Oncology ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Italy ,Oncology ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,Feasibility Studies ,Humans ,Female ,Neoplasm Invasiveness ,Guideline Adherence ,Practice Patterns, Physicians' ,Aged ,Quality Indicators, Health Care - Abstract
Aims and background Project RIGHT (Research for the Identification of the most effective and hIGHly accepted clinical guidelines for cancer Treatment) is promoted by the Italian Association of Medical Oncology (AIOM) to evaluate the concordance between AIOM breast cancer guidelines and clinical practice in Italy. In RIGHT-1, feasibility and the appropriateness of indicators were assessed in patients with early breast cancer. RIGHT-2 evaluated the compliance with guidelines in a nationwide program. Methods Thirty-five Italian centers participated in the RIGHT-2 survey. Ten indicators were evaluated to verify an agreement between 2005 AIOM breast cancer guidelines and practice. Patients with clinical stage I-II invasive breast cancer, age ≤70 years, who had their first visit at the oncology center between October 2005 and November 2006 were included. Results In RIGHT-2, ≥90% adherence for the diagnosis indicator and three therapy indicators were observed. The lowest degree of compliance (0%) was observed for the follow-up indicator in asymptomatic patients. Conclusions In RIGHT-2, compliance to the 2005 AIOM breast cancer guidelines was 64%. When the follow-up indicator was eliminated, overall adherence to AIOM guidelines was 71%. The results highlight the need to continue improving the already good standards of breast cancer care.
- Published
- 2011
- Full Text
- View/download PDF
44. Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study
- Author
-
Pronzato, P., primary, Mustacchi, G., additional, Riccardi, F., additional, Turletti, A., additional, Michelotti, A., additional, Natoli, C., additional, Livi, L., additional, Del Mastro, L., additional, Donadio, M., additional, Garrone, O., additional, Giordano, M., additional, De Laurentiis, M., additional, Marchetti, P., additional, Montemurro, F., additional, Romagnoli, E., additional, De Placido, S., additional, Biganzoli, L., additional, and Cazzaniga, M., additional
- Published
- 2017
- Full Text
- View/download PDF
45. Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): focus on luminal cancers. Results from GIM13 - AMBRA study
- Author
-
Mustacchi, G., primary, Cazzaniga, M., additional, Giordano, M., additional, Garrone, O., additional, Donadio, M., additional, Del Mastro, L., additional, Livi, L., additional, Natoli, C., additional, Michelotti, A., additional, Turletti, A., additional, Riccardi, F., additional, Marchetti, P., additional, Montemurro, F., additional, Romagnoli, E., additional, De Placido, S., additional, Biganzoli, L., additional, Bisagni, G., additional, and Bria, E., additional
- Published
- 2017
- Full Text
- View/download PDF
46. From the CLEOPATRA study to real life: preliminary results from the G.O.N.O. SUPER trial
- Author
-
Garrone, O., primary, Cursano, M.C., additional, De Angelis, C., additional, Giarratano, T., additional, Saggia, C., additional, Beano, A., additional, Cazzaniga, M., additional, La Verde, N., additional, Milani, A., additional, Collovà, E., additional, Coltelli, L., additional, de Conciliis, E., additional, Vandone, A.M., additional, Airoldi, M., additional, D'Onofrio, L., additional, Bertolini, I., additional, Guarneri, V., additional, Donadio, M., additional, Riva, F., additional, and Merlano, M.C., additional
- Published
- 2017
- Full Text
- View/download PDF
47. Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer
- Author
-
Conte, P., primary, Conte, P., additional, Bisagni, G., additional, Frassoldati, A., additional, Brandes, A., additional, Cavanna, L., additional, Giotta, F., additional, Aieta, M., additional, Gebbia, V., additional, Musolino, A., additional, Garrone, O., additional, Donadio, M., additional, Cavazzini, G., additional, Turletti, A., additional, Zamagni, C., additional, Danese, S., additional, Ferro, A., additional, Piacentini, F., additional, Balduzzi, S., additional, D'Amico, R., additional, and Guarneri, V., additional
- Published
- 2017
- Full Text
- View/download PDF
48. Nab-paclitaxel in clinical practice: data from the MANTEL study
- Author
-
Vanella, P., primary, Garrone, O., additional, Saggia, C., additional, Bergnolo, P., additional, Beano, A., additional, Airoldi, M., additional, Turletti, A., additional, Castiglione, F., additional, Manzin, E., additional, Denaro, N., additional, de Conciliis, E., additional, Vandone, A.M., additional, Donadio, M., additional, Miraglio, E., additional, and Merlano, M.C., additional
- Published
- 2017
- Full Text
- View/download PDF
49. Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): From randomized trials to real-life setting: Results from GIM13 - AMBRA study
- Author
-
Mustacchi, G., primary, Cazzaniga, M., additional, Bria, E., additional, Bisagni, G., additional, Biganzoli, L., additional, Pronzato, P., additional, De Placido, S., additional, Romagnoli, E., additional, Montemurro, F., additional, Marchetti, P., additional, De Laurentiis, M., additional, Riccardi, F., additional, Turletti, A., additional, Michelotti, A., additional, Natoli, C., additional, Livi, L., additional, Del Mastro, L., additional, Donadio, M., additional, Garrone, O., additional, and Giordano, M., additional
- Published
- 2017
- Full Text
- View/download PDF
50. Adherence to International ESO-ESMO (ABC) guide-lines in HER2-ve metastatic breast cancer (MBC) patients (pts): Preliminary results of the GIM 13 - AMBRA Study
- Author
-
Cazzaniga, M., primary, Mustacchi, G., additional, Giordano, M., additional, Garrone, O., additional, Donadio, M., additional, del mastro, L., additional, Livi, L., additional, Natoli, C., additional, Michelotti, A., additional, Turletti, A., additional, Ferdinando, R., additional, De Laurentiis, M., additional, Marchetti, P., additional, Montemurro, M., additional, Romagnoli, E., additional, De Placido, S., additional, Pronzato, P., additional, Biganzoli, L., additional, Bisagni, G., additional, and Bria, E., additional
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.